E Bezard

Summary

Country: France

Publications

  1. ncbi request reprint Absence of MPTP-induced neuronal death in mice lacking the dopamine transporter
    E Bezard
    Basal Gang, CNRS UMR 5541, Laboratoire de Neurophysiologie, CNRS UMR 5543, Universite de Bordeaux II, 146 rue Leo Saignat, Bordeaux Cedex, 33076, France
    Exp Neurol 155:268-73. 1999
  2. pmc Normalization and expression changes in predefined sets of proteins using 2D gel electrophoresis: a proteomic study of L-DOPA induced dyskinesia in an animal model of Parkinson's disease using DIGE
    Kim Kultima
    Department of Pharmaceutical Biosciences, Division of Toxicology, Uppsala University, BMC, Box 594, SE 75124 Uppsala, Sweden
    BMC Bioinformatics 7:475. 2006
  3. ncbi request reprint Kinetics of nigral degeneration in a chronic model of MPTP-treated mice
    E Bezard
    Basal Gang, Laboratoire de Neurophysiologie, CNRS UMR 5543, Universite de Bordeaux II, France
    Neurosci Lett 234:47-50. 1997
  4. ncbi request reprint 5-HT1A receptor agonist-mediated protection from MPTP toxicity in mouse and macaque models of Parkinson's disease
    Erwan Bezard
    CNRS UMR 5543, Laboratoire de Physiologie et Physiopathologie de la Signalisation Cellulaire, Universite de Bordeaux 2, 146 rue Leo Saignat, 33076 Bordeaux Cedex, France
    Neurobiol Dis 23:77-86. 2006
  5. ncbi request reprint Upregulation of striatal preproenkephalin gene expression occurs before the appearance of parkinsonian signs in 1-methyl-4-phenyl- 1,2,3,6-tetrahydropyridine monkeys
    E Bezard
    Manchester Movement Disorder Laboratory, Division of Neuroscience, School of Biological Sciences, University of Manchester, 1 124 Stopford Building, Manchester, M13 9 PT, United Kingdom
    Neurobiol Dis 8:343-50. 2001
  6. ncbi request reprint Pallidal border cells: an anatomical and electrophysiological study in the 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine-treated monkey
    E Bezard
    Manchester Movement Disorder Laboratory, Division of Neuroscience, School of Biological Sciences, University of Manchester, 1 124 Stopford Building, Manchester M13 9PT, UK
    Neuroscience 103:117-23. 2001
  7. ncbi request reprint Sonic hedgehog is a neuromodulator in the adult subthalamic nucleus
    Erwan Bezard
    Basal Gang and CNRS UMR 5543, Universite Victor Segalen, 33076 Bordeaux Cedex, France
    FASEB J 17:2337-8. 2003
  8. ncbi request reprint Relationship between the appearance of symptoms and the level of nigrostriatal degeneration in a progressive 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine-lesioned macaque model of Parkinson's disease
    E Bezard
    Manchester Movement Disorder Laboratory, Division of Neuroscience, School of Biological Sciences, University of Manchester, Manchester, M13 9PT, United Kingdom
    J Neurosci 21:6853-61. 2001
  9. ncbi request reprint A call for clinically driven experimental design in assessing neuroprotection in experimental Parkinsonism
    Erwan Bezard
    CNRS UMR 5543, Victor Segalen Bordeaux 2 University, Bordeaux, France
    Behav Pharmacol 17:379-82. 2006
  10. ncbi request reprint Neuroprotection for Parkinson's disease: a call for clinically driven experimental design
    Erwan Bezard
    Basal Gang, Laboratoire de Neurophysiologie, CNRS UMR 5543, Universite Victor Segalen, 33076, Bordeaux, France
    Lancet Neurol 2:393. 2003

Detail Information

Publications87

  1. ncbi request reprint Absence of MPTP-induced neuronal death in mice lacking the dopamine transporter
    E Bezard
    Basal Gang, CNRS UMR 5541, Laboratoire de Neurophysiologie, CNRS UMR 5543, Universite de Bordeaux II, 146 rue Leo Saignat, Bordeaux Cedex, 33076, France
    Exp Neurol 155:268-73. 1999
    ....
  2. pmc Normalization and expression changes in predefined sets of proteins using 2D gel electrophoresis: a proteomic study of L-DOPA induced dyskinesia in an animal model of Parkinson's disease using DIGE
    Kim Kultima
    Department of Pharmaceutical Biosciences, Division of Toxicology, Uppsala University, BMC, Box 594, SE 75124 Uppsala, Sweden
    BMC Bioinformatics 7:475. 2006
    ..This method was applied to our data generated from a monkey model (Macaca fascicularis) of Parkinson's disease...
  3. ncbi request reprint Kinetics of nigral degeneration in a chronic model of MPTP-treated mice
    E Bezard
    Basal Gang, Laboratoire de Neurophysiologie, CNRS UMR 5543, Universite de Bordeaux II, France
    Neurosci Lett 234:47-50. 1997
    ..This new protocol thus mirrors closely the pattern of evolution assumed to be that of Parkinson's disease and should prove useful for studies on neuroprotection and compensatory mechanisms...
  4. ncbi request reprint 5-HT1A receptor agonist-mediated protection from MPTP toxicity in mouse and macaque models of Parkinson's disease
    Erwan Bezard
    CNRS UMR 5543, Laboratoire de Physiologie et Physiopathologie de la Signalisation Cellulaire, Universite de Bordeaux 2, 146 rue Leo Saignat, 33076 Bordeaux Cedex, France
    Neurobiol Dis 23:77-86. 2006
    ..These results suggest that 5-HT1A agonists, such as BAY 639044, may protect from neurodegeneration and delay the worsening of motor symptoms in Parkinson patients...
  5. ncbi request reprint Upregulation of striatal preproenkephalin gene expression occurs before the appearance of parkinsonian signs in 1-methyl-4-phenyl- 1,2,3,6-tetrahydropyridine monkeys
    E Bezard
    Manchester Movement Disorder Laboratory, Division of Neuroscience, School of Biological Sciences, University of Manchester, 1 124 Stopford Building, Manchester, M13 9 PT, United Kingdom
    Neurobiol Dis 8:343-50. 2001
    ..Furthermore, when considered with recent electrophysiological and histochemical data, these findings question the functional significance of upregulated enkephalin transmission in the indirect striatopallidal pathway...
  6. ncbi request reprint Pallidal border cells: an anatomical and electrophysiological study in the 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine-treated monkey
    E Bezard
    Manchester Movement Disorder Laboratory, Division of Neuroscience, School of Biological Sciences, University of Manchester, 1 124 Stopford Building, Manchester M13 9PT, UK
    Neuroscience 103:117-23. 2001
    ..Moreover, the relative sparing of these dopaminergic fibers in parkinsonian monkeys suggests that they would exhibit specific adaptive properties totally different from those described in the nigrostriatal pathway...
  7. ncbi request reprint Sonic hedgehog is a neuromodulator in the adult subthalamic nucleus
    Erwan Bezard
    Basal Gang and CNRS UMR 5543, Universite Victor Segalen, 33076 Bordeaux Cedex, France
    FASEB J 17:2337-8. 2003
    ..As the subthalamic nucleus is overactive in parkinsonism, we suggest that enhancement of sonic hedgehog signaling in the subthalamic nucleus may be of therapeutic value in Parkinson's disease...
  8. ncbi request reprint Relationship between the appearance of symptoms and the level of nigrostriatal degeneration in a progressive 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine-lesioned macaque model of Parkinson's disease
    E Bezard
    Manchester Movement Disorder Laboratory, Division of Neuroscience, School of Biological Sciences, University of Manchester, Manchester, M13 9PT, United Kingdom
    J Neurosci 21:6853-61. 2001
    ....
  9. ncbi request reprint A call for clinically driven experimental design in assessing neuroprotection in experimental Parkinsonism
    Erwan Bezard
    CNRS UMR 5543, Victor Segalen Bordeaux 2 University, Bordeaux, France
    Behav Pharmacol 17:379-82. 2006
    ....
  10. ncbi request reprint Neuroprotection for Parkinson's disease: a call for clinically driven experimental design
    Erwan Bezard
    Basal Gang, Laboratoire de Neurophysiologie, CNRS UMR 5543, Universite Victor Segalen, 33076, Bordeaux, France
    Lancet Neurol 2:393. 2003
  11. ncbi request reprint Presymptomatic compensation in Parkinson's disease is not dopamine-mediated
    Erwan Bezard
    Basal Gang, Laboratoire de Neurophysiologie, CNRS UMR 5543, Universite Victor Segalen, 146 rue Leo Saignat, 33076 Bordeaux Cedex, France
    Trends Neurosci 26:215-21. 2003
    ....
  12. ncbi request reprint Spontaneous long-term compensatory dopaminergic sprouting in MPTP-treated mice
    E Bezard
    Basal Gang, Laboratoire de Neurophysiologie, CNRS UMR 5543, Universite de Bordeaux II, Bordeaux Cedex, France
    Synapse 38:363-8. 2000
    ....
  13. ncbi request reprint Adaptive changes in the nigrostriatal pathway in response to increased 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine-induced neurodegeneration in the mouse
    E Bezard
    Basal Gang, Laboratoire de Neurophysiologie, CNRS UMR 5543, Universite Victor Segalen, 146 rue Leo Saignat, 33076 Bordeaux Cedex, France
    Eur J Neurosci 12:2892-900. 2000
    ....
  14. ncbi request reprint A chronic MPTP model reproducing the slow evolution of Parkinson's disease: evolution of motor symptoms in the monkey
    E Bezard
    Laboratoire de Neurophysiologie, CNRS UMR 5543, Universite de Bordeaux II, France
    Brain Res 766:107-12. 1997
    ..This model so could be of great interest for the study of the dynamic physiopathological changes which occur in Parkinson's disease and consequently for research on new neuroprotective therapies...
  15. ncbi request reprint Effects of different schedules of MPTP administration on dopaminergic neurodegeneration in mice
    E Bezard
    Laboratoire de Neurophysiologie, CNRS UMR 5543, Universite de Bordeaux II, France
    Exp Neurol 148:288-92. 1997
    ..These mechanisms need to be better understood if chronic models of intoxication that replicate the evolution of human Parkinson's disease more precisely are to be developed...
  16. ncbi request reprint Compensatory mechanisms in experimental and human parkinsonism: towards a dynamic approach
    E Bezard
    Laboratoire de Neurophysiologie, CNRS UMR 5543, Universite de Bordeaux II, France
    Prog Neurobiol 55:93-116. 1998
    ..Only a dynamic approach to the physiopathological study of compensatory mechanisms in the basal ganglia will be capable of elucidating these complex questions...
  17. ncbi request reprint Involvement of the subthalamic nucleus in glutamatergic compensatory mechanisms
    E Bezard
    Basal Gang, Laboratoire de Neurophysiologie, CNRS UMR 5543, Universite de Bordeaux II, France
    Eur J Neurosci 11:2167-70. 1999
    ....
  18. ncbi request reprint Attenuation of levodopa-induced dyskinesia by normalizing dopamine D3 receptor function
    Erwan Bezard
    Basal Gang, Laboratoire de Neurophysiologie, CNRS UMR 5543, Universite Victor Segalen, 33076 Bordeaux, France
    Nat Med 9:762-7. 2003
    ....
  19. ncbi request reprint Toward a primate model of L-dopa-unresponsive parkinsonism mimicking striatonigral degeneration
    I Ghorayeb
    CNRS UMR 5543, Universite Victor Segalen Bordeaux 2, France
    Mov Disord 15:531-6. 2000
    ..The double-lesion primate model of SND may serve as a preclinical test-bed for the evaluation of novel therapeutic strategies in MSA-P...
  20. ncbi request reprint Effects of L-DOPA on neuronal activity of the globus pallidus externalis (GPe) and globus pallidus internalis (GPi) in the MPTP-treated monkey
    T Boraud
    Basal Gang, Lab Neurophysiologie, CNRS UMR 5543, Universite Victor Segalen Bordeaux 2, 146, rue Leo Saignat, 33076 Bordeaux Cedex, France
    Brain Res 787:157-60. 1998
    ..A slight reduction was observed in bursting activity. These unexpected results would show that the normalizing effect of L-DOPA on GPi output is limited...
  21. ncbi request reprint Effects of riluzole on the electrophysiological activity of pallidal neurons in the 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine-treated monkey
    T Boraud
    Basal Gang, CNRS UMR 5543, Universite Victor Segalen Bordeaux 2, 146 rue Leo Saignat, 33076 Bordeaux, Cedex, France
    Neurosci Lett 281:75-8. 2000
    ..Riluzole would represent an interesting alternative to dopamine therapy in Parkinson's disease since it regularizes firing but does not cause dyskinesia...
  22. ncbi request reprint Levodopa-induced dyskinesia in MPTP-treated macaques is not dependent on the extent and pattern of nigrostrial lesioning
    Celine Guigoni
    Laboratoire de Physiologie et Physiopathologie de la Signalization Cellulaire, CNRS UMR 5543, Universite Victor Segalen Bordeaux, 33076 Bordeaux Cedex, France
    Eur J Neurosci 22:283-7. 2005
    ..These data indicate that neither the extent nor the pattern of nigrostriatal lesioning are sufficient to explain the occurrence of levodopa-induced dyskinesia...
  23. ncbi request reprint Compensatory regulation of striatal neuropeptide gene expression occurs before changes in metabolic activity of basal ganglia nuclei
    Wassilios Meissner
    Basal Gang, Laboratoire de Neurophysiologie, CNRS UMR 5543, Universite Victor Segalen, 146 rue Leo Saignat, 33076, Bordeaux Cedex, France
    Neurobiol Dis 13:46-54. 2003
    ..It also indicates that nondopaminergic compensatory mechanisms inherent to the basal ganglia are activated before those residing outside the basal ganglia...
  24. ncbi request reprint Pattern of levodopa-induced striatal changes is different in normal and MPTP-lesioned mice
    Christian E Gross
    Basal Gang, Laboratoire de Neurophysiologie, Universite Victor Segalen, Bordeaux Cedex, France
    J Neurochem 84:1246-55. 2003
    ....
  25. ncbi request reprint Dopamine agonist-induced dyskinesias are correlated to both firing pattern and frequency alterations of pallidal neurones in the MPTP-treated monkey
    T Boraud
    Basal Gang, CNRS UMR 5543, , 146, , 33076 Bordeaux Cedex, France
    Brain 124:546-57. 2001
    ..However, the similarity between the induced decrease in firing frequency in normal and parkinsonian animals underlines the need for dopamine depletion in the induction of dyskinesias...
  26. ncbi request reprint Pathophysiology of levodopa-induced dyskinesia: potential for new therapies
    E Bezard
    Basal Gang, Laboratoire de Neurophysiologie, CNRS UMR 5543, , , 33076 Bordeaux Cedex, France
    Nat Rev Neurosci 2:577-88. 2001
    ..Our increased understanding of levodopa-induced dyskinesia is not only valuable for improving patient care, but also in providing us with new insights into the functional organization of the basal ganglia and motor systems...
  27. ncbi request reprint Increased D1 dopamine receptor signaling in levodopa-induced dyskinesia
    Incarnation Aubert
    Centre National de la Recherche Scientifique Unite Mixte de Recherche 5541, Bordeaux Cedex, France
    Ann Neurol 57:17-26. 2005
    ..Our data suggest that levodopa-induced dyskinesia results from increased dopamine D(1) receptor-mediated transmission at the level of the direct pathway...
  28. ncbi request reprint L-DOPA reverses the MPTP-induced elevation of the arrestin2 and GRK6 expression and enhanced ERK activation in monkey brain
    E Bezard
    Basal Gang, CNRS UMR 5543, Universite Victor Segalen Bordeaux 2, 33076 Bordeaux Cedex, France
    Neurobiol Dis 18:323-35. 2005
    ..The data suggest the involvement of arrestins and GRKs in Parkinson disease pathology and the effects of levodopa treatment...
  29. ncbi request reprint Phenotype of striatofugal medium spiny neurons in parkinsonian and dyskinetic nonhuman primates: a call for a reappraisal of the functional organization of the basal ganglia
    Agnes Nadjar
    Centre National de la Recherche Scientifique Unité Mixte de Recherche 5543, Universite Victor Segalen Bordeaux 2, 33076 Bordeaux, France
    J Neurosci 26:8653-61. 2006
    ..Striatofugal pathways are not as segregated in the primate as previously considered...
  30. ncbi request reprint Altered D(1) dopamine receptor trafficking in parkinsonian and dyskinetic non-human primates
    Celine Guigoni
    CNRS UMR 5227, Universite Victor Segalen Bordeaux 2, 146 rue Leo Saignat, 33076 Bordeaux, France
    Neurobiol Dis 26:452-63. 2007
    ..Further experiments including parkinsonian monkeys chronically treated with L-dopa that show no dyskinesia and parkinsonian monkeys treated only once with L-dopa are now necessary to confirm our hypothesis...
  31. ncbi request reprint Enhanced preproenkephalin-B-derived opioid transmission in striatum and subthalamic nucleus converges upon globus pallidus internalis in L-3,4-dihydroxyphenylalanine-induced dyskinesia
    Incarnation Aubert
    Centre National de la Recherche Scientifique CNRS Unité Mixte de Recherche UMR 5541, Bordeaux Cedex, France
    Biol Psychiatry 61:836-44. 2007
    ....
  32. ncbi request reprint Increased slow oscillatory activity in substantia nigra pars reticulata triggers abnormal involuntary movements in the 6-OHDA-lesioned rat in the presence of excessive extracellular striatal dopamine
    Wassilios Meissner
    Laboratoire de Physiologie et Physiopathologie de la Signalisation Cellulaire, CNRS UMR 5543, Universite Victor Segalen, 146 rue Leo Saignat, 33076 Bordeaux Cedex, France
    Neurobiol Dis 22:586-98. 2006
    ....
  33. ncbi request reprint Involvement of sensorimotor, limbic, and associative basal ganglia domains in L-3,4-dihydroxyphenylalanine-induced dyskinesia
    Celine Guigoni
    Basal Gang, Centre National de la Recherche Scientifique CNRS Unité Mixte de Recherche UMR 5543, Universite Victor Segalen Bordeaux 2, 33076 Bordeaux Cedex, France
    J Neurosci 25:2102-7. 2005
    ..We propose that these metabolic changes reflect the underlying neural mechanisms of not simply motor dyskinesias but also affective, motivational, and cognitive disorders associated with long-term exposure to L-dopa...
  34. ncbi request reprint From experimentation to the surgical treatment of Parkinson's disease: prelude or suite in basal ganglia research?
    C E Gross
    Basal Gang, Laboratoire de Neurophysiologie, CNRS UMR 5543, Universite de Bordeaux, France
    Prog Neurobiol 59:509-32. 1999
    ..All the more reason, in consequence, for extending experimental investigation into the impact of any new therapy before proposing its clinical application...
  35. doi request reprint Subthalamic stimulation increases striatal tyrosine hydroxylase phosphorylation
    Rene Reese
    CNRS UMR 5227, Bordeaux, France
    Neuroreport 19:179-82. 2008
    ..Our results suggest that subthalamic stimulation may increase tyrosine hydroxylase activity via increased phosphorylation...
  36. ncbi request reprint Asymmetrically lesioned mesencephalon in healthy rodents: call for caution
    Elsa Y Pioli
    Basal Gang, Laboratoire de Physiologie et Physiopathologie de la Signalisation Cellulaire, CNRS UMR 5543, Universite Victor Segalen, 146 rue Leo Saignat, 33076 Bordeaux Cedex, France
    Brain Res 1022:251-3. 2004
    ..This potential bias in assessing extent of neurotoxin-induced lesion and subsequent protection by pharmacological manipulation prompts us to call for caution in setting up experimental designs...
  37. ncbi request reprint Deleterious effects of minocycline in animal models of Parkinson's disease and Huntington's disease
    Elsa Diguet
    Physiologie et Physiopathologie de la Signalization Cellulaire, UMR CNRS 5543, Université Victor Segalen Bordeaux2, 146 rue Leo Saignat, 33076, Bordeaux, France
    Eur J Neurosci 19:3266-76. 2004
    ..Thus, minocycline may have variable and even deleterious effects in different species and models according to the mode of administration and dose...
  38. ncbi request reprint Electrophysiological and metabolic evidence that high-frequency stimulation of the subthalamic nucleus bridles neuronal activity in the subthalamic nucleus and the substantia nigra reticulata
    Chun Hwei Tai
    Laboratoire de Neurophysiologie, Basal Gang, CNRS UMR 5543, Universite Victor Segalen, 146, rue Leo Saignat, 33076 Bordeaux Cedex, France
    FASEB J 17:1820-30. 2003
    ..These data afford an interesting insight into the functional mechanism of deep brain stimulation and support the hypothesis that HFS exerts an inhibitory influence on STN neuronal firing...
  39. ncbi request reprint Levetiracetam Interferes With the L-dopa priming process in MPTP-lesioned drug-naive marmosets
    Michael P Hill
    Motac Neuroscience, Ltd, Manchester, UK
    Clin Neuropharmacol 27:171-7. 2004
    ..This study investigated whether LEV can modify induction of dyskinesia by l-dopa or the process of priming...
  40. ncbi request reprint Noradrenergic modulation of subthalamic nucleus activity: behavioral and electrophysiological evidence in intact and 6-hydroxydopamine-lesioned rats
    Pauline Belujon
    Centre National de la Recherche Scientifique, Unité Mixte de Recherche 5227, Universite Victor Segalen, 33076 Bordeaux Cedex, France
    J Neurosci 27:9595-606. 2007
    ....
  41. ncbi request reprint Time-course of nigrostriatal degeneration in a progressive MPTP-lesioned macaque model of Parkinson's disease
    Wassilios Meissner
    Basal Gang, Laboratoire de Neurophysiologie, CNRS UMR 5543, Universite Victor Segalen, 146 rue Leo Saignat, 33076 Bordeaux Cedex, France
    Mol Neurobiol 28:209-18. 2003
    ..In this article, we examine how this and other chronic MPTP models fit with human pathology...
  42. ncbi request reprint High-frequency stimulation of both zona incerta and subthalamic nucleus induces a similar normalization of basal ganglia metabolic activity in experimental parkinsonism
    Abdelhamid Benazzouz
    Basal Gang, Laboratoire de Physiologie et Physiopathologie de la Signalization Cellulaire, CNRS UMR 5543, Universite Victor Segalen, Bordeaux, France
    FASEB J 18:528-30. 2004
    ..These data suggest that the ZI, as well as the STN, are implicated in the functional mechanism of HFS supporting the involvement of GABA transmission for the reduction of neuronal activity in the basal ganglia output structures...
  43. ncbi request reprint Impact of chronic subthalamic high-frequency stimulation on metabolic basal ganglia activity: a 2-deoxyglucose uptake and cytochrome oxidase mRNA study in a macaque model of Parkinson's disease
    Wassilios Meissner
    CNRS UMR 5227, Universite Victor Segalen, 146 rue Leo Saignat, 33076 Bordeaux Cedex, France
    Eur J Neurosci 25:1492-500. 2007
    ....
  44. pmc Misrepresentation of neuroscience data might give rise to misleading conclusions in the media: the case of attention deficit hyperactivity disorder
    Francois Gonon
    Institut des Maladies Neurodégénératives, University of Bordeaux, Bordeaux, France
    PLoS ONE 6:e14618. 2011
    ..There is often a huge gap between neurobiological facts and firm conclusions stated by the media. Data misrepresentation in the conclusions and summaries of neuroscience articles might contribute to this gap...
  45. doi request reprint IGF-1 signaling reduces neuro-inflammatory response and sensitivity of neurons to MPTP
    Agnes Nadjar
    Universite Victor Segalen Bordeaux 2, Centre National de la Recherche Scientifique, Bordeaux Institute of Neuroscience, UMR 5227, Bordeaux, France
    Neurobiol Aging 30:2021-30. 2009
    ..Collectively, these data indicate that IGF signaling can reduce neuro-inflammation dependent sensitivity of neurons to MPTP...
  46. ncbi request reprint Pathogenesis of levodopa-induced dyskinesia: focus on D1 and D3 dopamine receptors
    C Guigoni
    Basal Gang, Laboratoire de Physiologie et Physiopathologie de la Signalisation Cellulaire, CNRS UMR 5543, Universite Victor Segalen Bordeaux 2, France
    Parkinsonism Relat Disord 11:S25-9. 2005
    ..We also report the possible role of arrestin and G protein-coupled receptor kinases...
  47. doi request reprint [Striatal proteomic analysis suggests that first L-dopa dose equates to chronic exposure]
    Erwan Bezard
    UMR CNRS 5227, Mouvement Adaptation Cognition, 146, rue Leo Saignat, 33076 Bordeaux edex, France
    Med Sci (Paris) 24:368. 2008
  48. ncbi request reprint Partial bilateral mesencephalic lesions affect D1 but not D2 binding in both the striatum and cortex
    Elsa Pioli
    Basal Gang, Laboratoire de Physiologie et Physiopathologie de la Signalisation Cellulaire, CNRS UMR 5543, Universite Victor Segalen, 146 rue Leo Saignat, 33076 Bordeaux Cedex, France
    Neurochem Int 45:995-1004. 2004
    ..Further behavioural experiments may explain the pathophysiological meaning of increased cortical D(1) binding, and determine whether this observation is involved in compensatory mechanisms...
  49. pmc Dopamine transporter binding is unaffected by L-DOPA administration in normal and MPTP-treated monkeys
    Pierre Olivier Fernagut
    Universite Victor Segalen Bordeaux 2, Centre National de la Recherche Scientifique, Bordeaux Institute of Neuroscience, UMR 5227, Bordeaux, France
    PLoS ONE 5:e14053. 2010
    ..Thus, results of these studies may have been affected by factors other than the primary biological process investigated...
  50. ncbi request reprint Levetiracetam potentiates the antidyskinetic action of amantadine in the 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP)-lesioned primate model of Parkinson's disease
    Michael P Hill
    Motac Neuroscience Ltd, Manchester, United Kingdom
    J Pharmacol Exp Ther 310:386-94. 2004
    ..Combined LEV/amantadine therapy might be useful as an adjunct to L-DOPA to treat dyskinetic side effects and to expand the population of Parkinson's disease patients who benefit from treatment with amantadine alone...
  51. doi request reprint Differential behavioral effects of partial bilateral lesions of ventral tegmental area or substantia nigra pars compacta in rats
    E Y Pioli
    Universite Victor Segalen, Bordeaux 2, Centre National de la Recherche Scienctifique, Bordeaux Institute of Neuroscience, UMR 5227, 146 rue Leo Saignat, Bordeaux Cedex, France
    Neuroscience 153:1213-24. 2008
    ..SNc-lesioned rats exhibited deficits in fine motor functions as previously described in animal models of Parkinson's disease, whereas VTA-lesioned rats demonstrated traits of perseveration without significant motor impairments...
  52. ncbi request reprint [Animal models of parkinsonism]
    I Ghorayeb
    Laboratoire de Neurophysiologie, CNRS UMR 5543, Universite Victor Segalen Bordeaux 2, Bordeaux
    Rev Neurol (Paris) 161:907-15. 2005
    ..We conclude that the use and improvement of both phenotypic and genetic models can significantly speed progress toward understanding the pathophysiology of these devastating diseases and finding innovative cures...
  53. pmc Priming for l-dopa-induced dyskinesia in Parkinson's disease: a feature inherent to the treatment or the disease?
    Agnes Nadjar
    Universite Victor Segalen Bordeaux 2, Centre National de la Recherche Scientifique, Bordeaux Institute of Neuroscience, CNRS UMR 5227, 146 rue Leo Saignat, Bordeaux 33076, France
    Prog Neurobiol 87:1-9. 2009
    ..Chronicity and pulsatility of subsequent dopaminergic treatment only exacerbates the likelihood of developing dyskinesia...
  54. doi request reprint Pharmacological analysis demonstrates dramatic alteration of D1 dopamine receptor neuronal distribution in the rat analog of L-DOPA-induced dyskinesia
    Amandine Berthet
    Universite Victor Segalen Bordeaux 2, Centre National de Recherche Scientifique, Bordeaux Institute of Neuroscience, UMR 5227, 33076 Bordeaux Cedex, France
    J Neurosci 29:4829-35. 2009
    ....
  55. doi request reprint The nigrostriatal pathway in Creutzfeldt-Jakob disease
    Anne Vital
    Universite Victor Segalen Bordeaux 2, Centre National de la Recherche Scientifique, Bordeaux Institute of Neuroscience, Bordeaux University Hospital, Bordeaux, France
    J Neuropathol Exp Neurol 68:809-15. 2009
    ..These findings suggest a possible pathophysiological overlap of abnormal protein aggregation in CJD and Parkinson disease...
  56. doi request reprint High frequency stimulation of the entopeduncular nucleus sets the cortico-basal ganglia network to a new functional state in the dystonic hamster
    Rene Reese
    Universite Victor Segalen Bordeaux 2, Centre National de la Recherche Scientifique, Bordeaux Institute of Neuroscience, UMR 5227, 33076 Bordeaux Cedex, France
    Neurobiol Dis 35:399-405. 2009
    ..EP-HFS had no effect on COI expression. The present results suggest that EP-HFS induces a new network activity state which may improve information processing and finally reduces the severity of dystonic attacks in dt(sz)-hamsters...
  57. ncbi request reprint Neuroprotective strategies for Parkinson's disease: conceptual limits of animal models and clinical trials
    Wassilios Meissner
    Basal Gang in Laboratoire de Neurophysiologie, CNRS UMR 5543, Universite Victor Segalen Bordeaux 2, 146 rue Leo Saignat, 33076 Bordeaux Cedex, France
    Trends Pharmacol Sci 25:249-53. 2004
    ..This lack of published data, associated with the conceptual limits of the current way of testing drugs in clinical trials, prompts us to argue for further preclinical validation of the 12 candidates...
  58. ncbi request reprint Temporal and spatial alterations in GPi neuronal encoding might contribute to slow down movement in Parkinsonian monkeys
    Arthur Leblois
    Basal Gang, Laboratoire de Neurophysiologie, CNRS UMR 5543, Universite Victor Segalen, 146 rue Leo Saignat, 33076 Bordeaux Cedex, France
    Eur J Neurosci 24:1201-8. 2006
    ..Parkinsonian bradykinesia could thus result from an impairment of both temporal and spatial specificity of the GPi response to movement...
  59. ncbi request reprint Novel antiepileptic drug levetiracetam decreases dyskinesia elicited by L-dopa and ropinirole in the MPTP-lesioned marmoset
    Michael P Hill
    Motac Neuroscience Ltd, Manchester, United Kingdom
    Mov Disord 18:1301-5. 2003
    ....
  60. ncbi request reprint Levetiracetam improves choreic levodopa-induced dyskinesia in the MPTP-treated macaque
    Erwan Bezard
    Basal Gang, Laboratoire de Neurophysiologie, CNRS UMR 5543, Universite Victor Segalen Bordeaux 2, 146 rue Leo Saignat, BP 28, 33076 Bordeaux Cedex, France
    Eur J Pharmacol 485:159-64. 2004
    ..These results suggest that levetiracetam may provide a novel therapeutic approach specifically aimed at the choreic form of levodopa-induced dyskinesia...
  61. ncbi request reprint Rise and fall of minocycline in neuroprotection: need to promote publication of negative results
    Elsa Diguet
    CNRS UMR 5543, Université Victor Segalen Bordeaux2, Bordeaux, France
    Exp Neurol 189:1-4. 2004
    ....
  62. ncbi request reprint Preclinical development of gene therapy for Parkinson's disease
    Gregory Porras
    CNRS UMR 5227, Universite Victor Segalen Bordeaux 2, 33076, Bordeaux, France
    Exp Neurol 209:72-81. 2008
    ..This, combined with the key feature of gene delivery that offers access to intracellular signalling pathways, is likely to further expand the number of proposed targets to be studied...
  63. ncbi request reprint Enriched environment confers resistance to 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine and cocaine: involvement of dopamine transporter and trophic factors
    Erwan Bezard
    Basal Gang, Centre National de la Recherche Scientifique Unité Mixte de Recherche 5543, Universite Victor Segalen, 33076 Bordeaux Cedex, France
    J Neurosci 23:10999-1007. 2003
    ..Furthermore, they suggest that the probability of developing neurological disorders such as Parkinson's disease or vulnerability to psychostimulants may be related to life experience...
  64. doi request reprint Sleep disorders in Parkinson's disease: the contribution of the MPTP non-human primate model
    Quentin Barraud
    Universite Victor Segalen Bordeaux 2, Centre National de la Recherche Scientifique, Bordeaux Institute of Neuroscience, UMR 5227 and Centre Hospitalier et Universitaire de Bordeaux, 146 rue Leo Saignat, 33076 Bordeaux Cedex, France
    Exp Neurol 219:574-82. 2009
    ..Ultimately, this may help in deciphering the specific role of dopamine depletion in the occurrence of these disorders...
  65. doi request reprint Involvement of canonical and non-canonical D1 dopamine receptor signalling pathways in L-dopa-induced dyskinesia
    Celine Guigoni
    Universite Victor Segalen Bordeaux 2, Centre National de la Recherche Scientifique, Bordeaux Institute of Neuroscience, UMR 5227, Bordeaux, France
    Parkinsonism Relat Disord 15:S64-7. 2009
    ..Experiments were performed in both the rodent and primate models of LID. Those results strongly suggest that different strategies might represent a treatment option for managing LID in PD...
  66. doi request reprint Dopamine receptors and L-dopa-induced dyskinesia
    Amandine Berthet
    Universite Victor Segalen Bordeaux 2, Centre National de la Recherche Scientifique, Bordeaux Institute of Neuroscience, UMR 5227, Bordeaux, France
    Parkinsonism Relat Disord 15:S8-12. 2009
    ..As more molecular tools are made available, we will better understand the role of each receptor and its associated signalling cascade in Parkinson's disease and L-dopa-induced dyskinesia, hopefully in a way amenable to patients...
  67. ncbi request reprint The deafferented nonhuman primate is not a reliable model of intractable pain
    Elsa Y Pioli
    Basal Gang, Laboratoire de Neurophysiologie, CNRS UMR, 5543, Universite Victor Segalen, 146 rue Leo Saignat, 33076 Bordeaux, France
    Neurol Res 25:127-9. 2003
    ..Our results do not exclude the possibility that the deafferentiation is still painful for the monkeys, but they definitely rule out that autotomy is a consistent response to deafferentation...
  68. ncbi request reprint Shaping of motor responses by incentive values through the basal ganglia
    Benjamin Pasquereau
    Basal Gang, Laboratoire de Neurophysiologie, Centre National de la Recherche Scientifique, Unité Mixte de Recherche 5227, Universite Victor Segalen, 33076 Bordeaux, France
    J Neurosci 27:1176-83. 2007
    ....
  69. doi request reprint Striatal histone modifications in models of levodopa-induced dyskinesia
    Anthony P Nicholas
    Center for Neurodegeneration and Experimental Therapeutics, Department of Neurology, University of Alabama at Birmingham, AL 35294 0017, USA
    J Neurochem 106:486-94. 2008
    ..However, both models exhibit marked deacetylation of histone H4, suggesting that inhibitors of H4 deacetylation may be useful in preventing or reversing LDID...
  70. doi request reprint The 3-hydroxy-3-methylglutaryl-CoA reductase inhibitor lovastatin reduces severity of L-DOPA-induced abnormal involuntary movements in experimental Parkinson's disease
    Stefan Schuster
    Boehringer Ingelheim Pharma GmbH, 88397 Biberach, Germany
    J Neurosci 28:4311-6. 2008
    ..Those results strongly suggest that lovastatin might represent a treatment option for managing LID in PD...
  71. ncbi request reprint Brain-derived neurotrophic factor and the plasticity of the mesolimbic dopamine pathway
    Oliver Guillin
    Unité de Neurobiologie et Pharmacologie Moléculaire, INSERM U 573, Centre Paul Broca, 75014 Paris, France
    Int Rev Neurobiol 59:425-44. 2004
  72. ncbi request reprint Effect of the D3 dopamine receptor partial agonist BP897 [N-[4-(4-(2-methoxyphenyl)piperazinyl)butyl]-2-naphthamide] on L-3,4-dihydroxyphenylalanine-induced dyskinesias and parkinsonism in squirrel monkeys
    Albert Hsu
    The Parkinson s Institute, 1170 Morse Ave, Sunnyvale, CA 94089, USA
    J Pharmacol Exp Ther 311:770-7. 2004
    ..These results suggest that BP897 may be less effective than originally anticipated for treating LIDs in Parkinson's disease...
  73. pmc Striatal proteomic analysis suggests that first L-dopa dose equates to chronic exposure
    Birger Scholz
    Department of Pharmaceutical Biosciences, Uppsala Biomedicinska Centrum BMC, Uppsala University, Uppsala, Sweden
    PLoS ONE 3:e1589. 2008
    ....
  74. ncbi request reprint Protective effects of green tea polyphenols in the 6-OHDA rat model of Parkinson's disease through inhibition of ROS-NO pathway
    Shuhong Guo
    State Key Laboratory of Brain and Cognitive Science, Institute of Biophysics, Academia Sinica, Beijing, China
    Biol Psychiatry 62:1353-62. 2007
    ..Our in vitro experiments suggested that green tea polyphenols (GTP) might protect dopamine neurons through inhibition of NO and reactive oxygen species (ROS)...
  75. ncbi request reprint High frequency stimulation of the entopeduncular nucleus has no effect on striatal dopaminergic transmission
    Wassilios Meissner
    Department of Neurology, Charite Campus Virchow, Humboldt University Berlin, Berlin, Germany
    Neurochem Int 44:281-6. 2004
    ....
  76. ncbi request reprint Novel pharmacological targets for the treatment of Parkinson's disease
    Anthony H V Schapira
    University Department of Clinical Neurosciences, Royal Free and University College Medical School, University College London, Rowland Hill Street, London NW3 2PF, UK
    Nat Rev Drug Discov 5:845-54. 2006
    ....
  77. ncbi request reprint Rotigotine treatment partially protects from MPTP toxicity in a progressive macaque model of Parkinson's disease
    Dieter Scheller
    Schwarz BioSciences GmbH, Alfred Nobel Strasse 10, Monheim, Germany
    Exp Neurol 203:415-22. 2007
    ..However, the protection of nerve terminals was not detected using SPECT. The data suggest that rotigotine exerts partial protection but that conventional imaging would not be able to identify such protection...
  78. ncbi request reprint Brain-derived neurotrophic factor controls dopamine D3 receptor expression: therapeutic implications in Parkinson's disease
    Olivier Guillin
    Unité de Neurobiologie et Pharmacologie Moléculaire, INSERM U 573, Centre Paul Broca, 2 ter rue d Alesia, 75014, Paris, France
    Eur J Pharmacol 480:89-95. 2003
    ....
  79. ncbi request reprint Microarray analysis of nonhuman primates: validation of experimental models in neurological disorders
    Marketa Marvanova
    Functional Genomics and Bioinformatics Laboratory, Department of Neurobiology, A I Virtanen Institute, University of Kuopio, 70211 Kuopio, Finland
    FASEB J 17:929-31. 2003
    ..We demonstrate that transcript profiling of NHPs could provide comparative genomic data to validate and better focus experimental animal models of human neurological disorders...
  80. ncbi request reprint Absence of quasi-morphine withdrawal syndrome in adenosine A2A receptor knockout mice
    Ainhoa Bilbao
    Departamento de Psicobiologia, Instituto Universitario de Drogodependencias, Universidad Complutense, Madrid 28223, Spain
    Psychopharmacology (Berl) 185:160-8. 2006
    ..When combined with the opioid antagonist naloxone, methylxanthines produce a characteristic quasi-morphine withdrawal syndrome (QMWS) in opiate-naive animals...
  81. ncbi request reprint Protective effect of green tea polyphenols on the SH-SY5Y cells against 6-OHDA induced apoptosis through ROS-NO pathway
    Shuhong Guo
    Laboratory of Visual Information Processing, Center of Brain and Cognitive Science, Institute of Biophysics, Academia Sinica, Beijing 100101, People s Republic of China
    Free Radic Biol Med 39:682-95. 2005
    ..Our results show that the protective effects of GTP on SH-SY5Y cells are mediated, at least in part, by controlling the ROS-NO pathway...
  82. ncbi request reprint RGS9-2 negatively modulates L-3,4-dihydroxyphenylalanine-induced dyskinesia in experimental Parkinson's disease
    Stephen J Gold
    Department of Psychiatry, University of Texas Southwestern Medical Center at Dallas, Dallas, Texas 75390, USA
    J Neurosci 27:14338-48. 2007
    ..However, the findings also suggest that increasing RGS9-2 expression and/or function in PD patients may only be a suitable therapeutic strategy to control involuntary movements induced by nonselective DA agonist such as L-dopa...
  83. ncbi request reprint Neuroprotective effects of rotigotine in the acute MPTP-lesioned mouse model of Parkinson's disease
    Dieter Scheller
    Schwarz BioSciences GmbH, Alfred Nobel Strasse 10, Monheim, Germany
    Neurosci Lett 432:30-4. 2008
    ..These data suggest that rotigotine, at the doses employed, significantly protected dopamine neurons from degeneration in an acute mouse model of MPTP intoxication...
  84. ncbi request reprint From single extracellular unit recording in experimental and human Parkinsonism to the development of a functional concept of the role played by the basal ganglia in motor control
    Thomas Boraud
    Department of Physiology, Faculty of Medicine, The Hebrew University of Jerusalem, 12272 Ein Kerem Campus, 91120, Jerusalem, Israel
    Prog Neurobiol 66:265-83. 2002
    ..Then, the main successive theories aimed to explain the role played by BG in motor control are presented and discussed in the light of the most recently obtained results using the latest technological advances...
  85. ncbi request reprint Quantification of dopamine transporter by 123I-PE2I SPECT and the noninvasive Logan graphical method in Parkinson's disease
    Caroline Prunier
    Nuclear Medicine Department, Institut National de la Santé et de la Recherche Médicale Unit 316, Bretonneau Hospital, Tours, France
    J Nucl Med 44:663-70. 2003
    ....
  86. ncbi request reprint Traditional Chinese medicine for Parkinson's disease: a review of Chinese literature
    Qin Li
    Laboratory Animal Research Centre, China Agricultural University, Beijing, China
    Behav Pharmacol 17:403-10. 2006
    ....
  87. ncbi request reprint Investigating the receptor-independent neuroprotective mechanisms of nicotine in mitochondria
    Yu Xiang Xie
    State Key Laboratory of Brain and Cognitive Science, Institute of Biophysics, Academia Sinica, Beijing, China
    J Biol Chem 280:32405-12. 2005
    ..These results show that interaction of nicotine with mitochondria respiratory chain together with its antioxidant effects should be considered in the neuroprotective effects of nicotine...